Your browser doesn't support javascript.
loading
Intervention planning for Antibiotic Review Kit (ARK): a digital and behavioural intervention to safely review and reduce antibiotic prescriptions in acute and general medicine.
Santillo, M; Sivyer, K; Krusche, A; Mowbray, F; Jones, N; Peto, T E A; Walker, A S; Llewelyn, M J; Yardley, L.
Affiliation
  • Santillo M; Centre for Clinical and Community Applications of Health Psychology, University of Southampton, Southampton, UK.
  • Sivyer K; Centre for Clinical and Community Applications of Health Psychology, University of Southampton, Southampton, UK.
  • Krusche A; Centre for Clinical and Community Applications of Health Psychology, University of Southampton, Southampton, UK.
  • Mowbray F; Centre for Clinical and Community Applications of Health Psychology, University of Southampton, Southampton, UK.
  • Jones N; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Peto TEA; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Walker AS; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Llewelyn MJ; NIHR Biomedical Centre, Oxford, UK.
  • Yardley L; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
J Antimicrob Chemother ; 74(11): 3362-3370, 2019 11 01.
Article de En | MEDLINE | ID: mdl-31430366
ABSTRACT

BACKGROUND:

Hospital antimicrobial stewardship strategies, such as 'Start Smart, Then Focus' in the UK, balance the need for prompt, effective antibiotic treatment with the need to limit antibiotic overuse using 'review and revise'. However, only a minority of review decisions are to stop antibiotics. Research suggests that this is due to both behavioural and organizational factors.

OBJECTIVES:

To develop and optimize the Antibiotic Review Kit (ARK) intervention. ARK is a complex digital, organizational and behavioural intervention that supports implementation of 'review and revise' to help healthcare professionals safely stop unnecessary antibiotics.

METHODS:

A theory-, evidence- and person-based approach was used to develop and optimize ARK and its implementation. This was done through iterative stakeholder consultation and in-depth qualitative research with doctors, nurses and pharmacists in UK hospitals. Barriers to and facilitators of the intervention and its implementation, and ways to address them, were identified and then used to inform the intervention's development.

RESULTS:

A key barrier to stopping antibiotics was reportedly a lack of information about the original prescriber's rationale for and their degree of certainty about the need for antibiotics. An integral component of ARK was the development and optimization of a Decision Aid and its implementation to increase transparency around initial prescribing decisions.

CONCLUSIONS:

The key output of this research is a digital and behavioural intervention targeting important barriers to stopping antibiotics at review (see http//bsac-vle.com/ark-the-antibiotic-review-kit/ and http//antibioticreviewkit.org.uk/). ARK will be evaluated in a feasibility study and, if successful, a stepped-wedge cluster-randomized controlled trial at acute hospitals across the NHS.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Ordonnances médicamenteuses / Personnel de santé / Médecine générale / Gestion responsable des antimicrobiens / Antibactériens Type d'étude: Clinical_trials / Prognostic_studies / Qualitative_research / Sysrev_observational_studies Aspects: Implementation_research Limites: Humans Pays/Région comme sujet: Europa Langue: En Journal: J Antimicrob Chemother Année: 2019 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Ordonnances médicamenteuses / Personnel de santé / Médecine générale / Gestion responsable des antimicrobiens / Antibactériens Type d'étude: Clinical_trials / Prognostic_studies / Qualitative_research / Sysrev_observational_studies Aspects: Implementation_research Limites: Humans Pays/Région comme sujet: Europa Langue: En Journal: J Antimicrob Chemother Année: 2019 Type de document: Article Pays d'affiliation: Royaume-Uni